Are you ready to take TACE to the next level?

TACE is standard of care in the BCLC guidelines for HCC, and we recognise that there is still scope for improvement, for example complete response rates, duration of response, leading to the need for retreatment.

As Terumo we are proud that we have generated in recent years a large set of clinical data leading to a new concept of advanced TACE. Several recent clinical publications using the Terumo portfolio have shown new evidence to further improve TACE.

This evidence could further strengthen the case for TACE at the oncological tumour board.

Clinical Data

The latest clinical evidence with the Terumo portfolio in DEM-TACE and Occlusafe-TACE brings new perspectives on the future of TACE treatment:

A pooled analysis from over 580 patients with unrestable HCC treated with DEM-TACE will support your practice of DEM-TACE in tumour board discussions. This data is published in CVIR (2023) and was also presented in major oncological congresses, including ESMO GI 2020 and ASCO GI 2021.

Occlusafe-TACE combination data demonstrate significantly fewer retreatment for effective disease control within the first 6 months of follow up, vs TACE alone which may offer prolonged patient survival due to lower liver toxicity.

Learn more about Advanced TACE clinical data

Taking TACE to the next level

Our ultimate goal by taking TACE to the next level: to Prolong HCC patients Life expectancy.

Improving complete response rates and maintaining this response lead to an increase in overall survival¹:

DEM-TACE treatments reach high complete response rates¹

60.1% Complete response rate leading to over 4 years overall survival (50.8month) (n=580 patients)¹

Even when multiple treatments are required for larger, complex tumours²

20% of patients achieved complete response after 3rd or 4th TACE procedures (n=97)²

Taking TACE to the next level

Our ultimate goal by taking TACE to the next level: to Prolong HCC patients Life expectancy.

Improving complete response rates and maintaining this response lead to an increase in overall survival¹:

DEM-TACE treatments reach high complete response rates¹

60.1% Complete response rate leading to over 4 years overall survival (50.8month) (n=580 patients)¹

Even when multiple treatments are required for larger, complex tumours²

20% of patients achieved complete response after 3rd or 4th TACE procedures (n=97)²

Occlusafe^TM-TACE demonstrated to be efficient for the oncological management of HCC with the following results³:

Complete response in 58.9% of patients at 6 months³
Median local recurrence-free survival of 31.0 months³
Over 4 years mean Overall Survival with 50 months [namely 51.4 months for patients BCLC A and 42.1 for patients BCLC B1] vs an expected 2.5 years Overall survival in BCLC B patients⁴

Long term clinical outcomes demonstrate that Occlusafe B-TACE allows to get similar clinical outcomes as with LifePearl^TM microspheres¹ DEM-TACE but in HCC lesions > 3 cm³

Occlusafe^TM-TACE demonstrated to be efficient for the oncological management of HCC with the following results³:

Complete response in 58.9% of patients at 6 months³
Median local recurrence-free survival of 31.0 months³
Over 4 years mean Overall Survival with 50 months [namely 51.4 months for patients BCLC A and 42.1 for patients BCLC B1] vs an expected 2.5 years Overall survival in BCLC B patients⁴

References

1. Veloso Gomes et al Cardiovasc Intervent Radiol 2023 (Pooled analysis)

2. de Baere T et al. Cancers (Basel) 2020;12:E3405 (PARIS registry)

3. Lucatelli et al: Cardiovasc Intervent Radiol https://doi.org/10.1007/s00270-024-03779-w

4. Reig et al - BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update – journal of Hepatology VOLUME 76, ISSUE 3, P681-693, MARCH 202

Breaking new data with Advanced TACE

Watch the videos below - which are of presentations from ECIO 2021.

What the evidence says

Discover our clinical evidence and case studies concerning this topic.

Transarterial chemoembolization with anthracyclines-loaded polyethylene glycol drug eluting microspheres for the treatment of hepatocellular carcinoma: A pooled multicentric analysis of survival in 580 patients

Featured product: LifePearl™ Drug Elutable Microspheres

Balloon-Occluded Transarterial Chemoembolization: In which size range does it perform best? A comparison of its efficacy versus conventional Transarterial Chemoembolization, using Propensity score matching

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients

Featured product: LifePearl™ Drug Elutable Microspheres

Chemoembolization Alone or Associated with Bevacizumab for Therapy of Colorectal Cancer Metastases: Preliminary Results of a Randomized Study

Featured product: LifePearl™ Drug Elutable Microspheres

LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study

Featured product: LifePearl™ Drug Elutable Microspheres

Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards

Featured product: LifePearl™ Drug Elutable Microspheres

Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer

Featured product: LifePearl™ Drug Elutable Microspheres

Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry

Featured product: LifePearl™ Drug Elutable Microspheres

Safety, tolerability, and efficacy of transarterial chemoembolization using anthracyclines-loaded drug-eluting microspheres for treatment of patients with unresectable hepatocellular carcinoma: Pooled analyses

Featured product: LifePearl™ Drug Elutable Microspheres

The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolization in Colorectal Cancer Liver Metastases: Interim Analysis

Featured product: LifePearl™ Drug Elutable Microspheres

Advanced TACE Programme Studies

Featured products: LifePearl™ Drug Elutable Microspheres, Occlusafe™ Temporary Occlusion Balloon Microcatheter

Balloon-Occluded Transcatheter Arterial Chemoembolization (b- TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Microballoon-related interventions in various endovascular treatments of body trunk lesions

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Initial Experience with Balloon-Occluded Trans-catheter Arterial Chemoembolization (B-TACE) for Hepatocellular Carcinoma

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: Retrospective comparison with conventional super-selective TACE

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Efﬁcacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerations

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon- occluded Arterial Stump Pressure

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Safety and efﬁcacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma

Featured product: LifePearl™ Drug Elutable Microspheres

Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial micro balloon catheter for hepatocellular carcinoma: Technical and safety considerations

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Balloon-Occluded DEB-TACE for a single node HCC as bridge to transplantation

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Successful Balloon-Occluded DEB-TACE after failure of SIRT and DEB-TACE

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

SIRT with Occlusafe in unresectable HCC, portal vein thrombosis and high-flow fistula

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

Y90 SIRT with Occlusafe® Micro-Balloon Catheter infusion system in a patient with unresectable HCC: the right way

Featured product: Occlusafe™ Temporary Occlusion Balloon Microcatheter

LifePearl® loaded with doxorubicin - downstage a patient with HCC to reach liver transplant

Featured product: LifePearl™ Drug Elutable Microspheres

Lifepearl loaded with doxorubicin in a patient with HCC pre-transplant

Featured product: LifePearl™ Drug Elutable Microspheres

See all clinical evidence

Do you need more info about this product?

Our sales representatives are here for you.

Send us a message

First name *

Last name *

Function

Company *

Country * Type required

E-mail address *

Question *

I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*

I wish to receive information and marketing updates from Terumo.

* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public

For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.

Advanced TACE

Are you ready to take TACE to the next level?

Clinical Data

​Taking TACE to the next level

​Taking TACE to the next level

​Taking TACE to the next level

References

References

Breaking new data with Advanced TACE

What the evidence says

Transarterial chemoembolization with anthracyclines-loaded polyethylene glycol drug eluting microspheres for the treatment of hepatocellular carcinoma: A pooled multicentric analysis of survival in 580 patients

Balloon-Occluded Transarterial Chemoembolization: In which size range does it perform best? A comparison of its efficacy versus conventional Transarterial Chemoembolization, using Propensity score matching

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study

Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results

Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes

Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis

Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients

Chemoembolization Alone or Associated with Bevacizumab for Therapy of Colorectal Cancer Metastases: Preliminary Results of a Randomized Study

LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study

Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards

Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer

Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry

Safety, tolerability, and efficacy of transarterial chemoembolization using anthracyclines-loaded drug-eluting microspheres for treatment of patients with unresectable hepatocellular carcinoma: Pooled analyses

The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolization in Colorectal Cancer Liver Metastases: Interim Analysis

Advanced TACE Programme Studies

Balloon-Occluded Transcatheter Arterial Chemoembolization (b- TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results

Microballoon-related interventions in various endovascular treatments of body trunk lesions

Initial Experience with Balloon-Occluded Trans-catheter Arterial Chemoembolization (B-TACE) for Hepatocellular Carcinoma

Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases

Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study

Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: Retrospective comparison with conventional super-selective TACE

Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization

Efﬁcacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results

Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerations

Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon- occluded Arterial Stump Pressure

Safety and efﬁcacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma

Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma

A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma

Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial micro balloon catheter for hepatocellular carcinoma: Technical and safety considerations

Balloon-Occluded DEB-TACE for a single node HCC as bridge to transplantation

Successful Balloon-Occluded DEB-TACE after failure of SIRT and DEB-TACE

SIRT with Occlusafe in unresectable HCC, portal vein thrombosis and high-flow fistula

Y90 SIRT with Occlusafe® Micro-Balloon Catheter infusion system in a patient with unresectable HCC: the right way

LifePearl® loaded with doxorubicin - downstage a patient with HCC to reach liver transplant

Lifepearl loaded with doxorubicin in a patient with HCC pre-transplant

Do you need more info about this product?

Send us a message

Taking TACE to the next level

Taking TACE to the next level

Taking TACE to the next level